As of Thursday close, iBio Inc.’s (AMEX:IBIO) stock traded at $0.33. The average number of shares traded per day over the past five days has been 476,380 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.0284 fall in that time frame. In the last twenty days, the average volume was 694,335, while in the previous 50 days, it was 696,974.
Since last month, IBIO stock retreated -8.68%. Shares of the company fell to $0.2620 on 09/06/23, the lowest level in the past month. A 52-week high of $10.69 was reached on 03/21/23 after having rallying from a 52-week low of $0.26. Since the beginning of this year, IBIO’s stock price has dropped by -26.64% or -$0.1184, and marked a new high 12 times. However, the stock has declined by -96.95% since its 52-week high.
IBIO stock investors should be aware that iBio Inc. (IBIO) stock had its last reported insider trading activity 25 days ago on Aug 28. Brenner Martin, the of the company, disposed of 5,011 shares for $0.31 on Aug 28. It resulted in a $1,529 divestment by the insider. Brenner Martin sold 4,515 shares at an average price of $0.51 on Jul 27. The insider now owns 201,876 shares following the transaction. On Jul 12, Brenner Martin sold 47,020 shares at $0.59 apiece. The transaction was valued at $27,521.
Valuation Metrics
The stock’s beta is -3.15. Besides these, the trailing price-to-sales (P/S) ratio of 15.27, the price-to-book (PB) ratio of 0.25.
Financial Health
According to company report, the long-term debt-to-equity ratio for the quarter ending September 29 was 0.04, and the total debt-to-equity ratio was 0.85. Based on annual data, IBIO earned $2.17 million in gross profit and brought in $2.38 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -57.30%. Return on equity (ROE) for the past 12 months was -205.40%.
While analysts expected iBio Inc. to report -$1.85 quarterly earnings, the actual figure was -$2.05 per share, beating the consensus estimate by -10.80%. During the quarter, the company generated -$5.84 million in EBITDA. The liabilities of iBio Inc. were 27.0 million at the end of its most recent quarter ended September 29, and its total debt was $18.43 million. The value of shareholders’ equity is $16.8 million.
Technical Picture
This quick technical analysis looks at iBio Inc.’s (IBIO) price momentum. With a historical volatility rate of 149.16%, the RSI 9-day stood at 46.45% on 21 September.
With respect to its five-day moving average, the current iBio Inc. price is down by -8.01% percent or -$0.0284. At present, IBIO shares trade -5.75% below its 20-day simple moving average and -69.81% percent below its 100-day simple moving average. However, the stock is currently trading approximately -45.07% below its SMA50 and -80.82% below its SMA200.
Stochastic coefficient K was 39.84% and Stochastic coefficient D was 42.17%, while ATR was 0.0410. Given the Stochastic reading of 38.46% for the 14-day period, the RSI (14) reading has been calculated as 43.38%.
Analyst Ratings
JMP Securities launched its rating on iBio Inc. (AMEX: IBIO) to a Mkt outperform in a note to investors on November 29, 2021. iBio Inc. (IBIO) has been rated Hold by analysts. According to 0 brokerage firms, IBIO is a sell, and 1 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate iBio Inc. stock as buy, with 0 recommending it as overweight.
With a median target price of $1.00, the current consensus forecast for the stock is $1.00 – $1.00. Based on these forecasts, analysts predict iBio Inc. (IBIO) will achieve an average price target of $1.00.
